📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. (2021)

First Author: Kolamunnage-Dona R

Attributed to: EPSRC Centre for New Mathematical Sciences Capabilities for Healthcare Technologies funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2021.05.015

PubMed Identifier: 34052255

Publication URI: http://europepmc.org/abstract/MED/34052255

Type: Journal Article/Review

Volume: 75

Parent Publication: Journal of hepatology

Issue: 4

ISSN: 0168-8278